Astrazeneca PLC News Headlines

AZN 
$73.91
*  
0.25
0.34%
Get AZN Alerts
*Delayed - data as of Nov. 26, 2014  -  Find a broker to begin trading AZN now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    AZN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Update: AstraZeneca On A Hot Streak, Announces Positive Data From The Phase 3 Study Of Brodalumab
11/27/2014 12:36:00 AM - Seeking Alpha


AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study - Analyst Blog
11/26/2014 5:30:00 PM - Zacks.com


Intra-Cellular Commences Phase III Schizophrenia Study - Analyst Blog
11/26/2014 4:40:00 PM - Zacks.com


AstraZeneca's (AZN) Respiratory Drug Approved in the EU - Analyst Blog
11/26/2014 1:30:00 PM - Zacks.com


Today's Market: 7 Stocks Moving On News
11/26/2014 10:51:00 AM - Seeking Alpha


Health Care Sector Update for 11/26/2014: ARWR, AMGN, AZN
11/26/2014 8:43:52 AM - MT Newswires


5 Things Pfizer, Inc.'s Management Wants You to Know
11/26/2014 8:15:03 AM - Motley Fool


Psoriasis Drug Trial Meets Goals, Reimbursement Rate For Cologuard Finalized
11/26/2014 3:50:00 AM - RTT News


Amgen,AstraZeneca Report Positive Results From Phase 3 Study Of Brodalumab
11/25/2014 10:06:00 PM - RTT News


Jefferies Bumps Up Against Big Rivals as It Looks to Expand
11/25/2014 7:09:00 PM - Dow Jones Business News


Last Phase 3 brodalumab psoriasis trial successful
11/25/2014 4:47:00 PM - Seeking Alpha


Drug makers face pushback on pricey meds
11/25/2014 8:18:00 AM - Seeking Alpha


Update: AstraZeneca Wins EC Marketing Authorization For Duaklir Genuair
11/25/2014 5:35:00 AM - Seeking Alpha


Novartis' Psoriasis Drug Cosentyx Backed for EU Approval - Analyst Blog
11/24/2014 6:40:00 PM - Zacks.com


Tracking Dan Loeb's Third Point Portfolio - Q3 2014 Update
11/24/2014 2:26:00 AM - Seeking Alpha


AstraZeneca: Duaklir Genuair Gets EU Marketing Authorisation For COPD
11/24/2014 2:21:00 AM - RTT News


Stop Worrying About Ebola: This is a Much More Pressing Concern
11/22/2014 3:04:08 PM - Motley Fool


Is It Time To Shift Into European Equities?
11/22/2014 5:47:00 AM - Seeking Alpha


Merck Collaboration Rules Out AstraZeneca Acquisition--For Now
11/21/2014 3:06:00 PM - Seeking Alpha


Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
11/21/2014 12:21:00 PM - Seeking Alpha


AstraZeneca Announces $200 Mln Expansion At Frederick Biologics Center
11/21/2014 11:31:00 AM - RTT News


Sanofi Beats The Drum
11/20/2014 1:19:00 PM - Seeking Alpha


What Does The U.S. Dollar Bull Market Mean For European Equities?
11/20/2014 12:38:00 PM - Seeking Alpha


Astrazeneca (AZN) Downgraded From Buy to Hold
11/20/2014 9:25:00 AM - TheStreet


The Crucial Thing You're Missing About Many Dividend Stocks
11/20/2014 8:35:03 AM - Motley Fool